KRAS and cancer: Two cell lines for each cancer type were assessed: A549 (adenocarcinoma) and H226 (squamous carcinoma) for lung, MCF-7 (estrogen receptor (ER)-positive) and MDA-MB-231 (ER-negative) for breast, LNCaP (androgen receptor (AR)-positive) and PC3-M (AR-negative) for prostate, and HCT116 (wildtype p53, mutated KRAS) and HT29 (p53 mutant) for colon [20].